Revisión sobre el uso del metilfenidato para el tratamiento de la astenia en pacientes paliativos.
Palabras clave:
"metilfenidato". "fatiga". "astenia relacionada con cancer". "pacientes paliativos". "cancer".Resumen
La astenia o fatiga, es uno de los síntomas mas frecuentes en el paciente paliativo. Uno de los tratamientos mas empleados para combatir la misma es el metilfenidato. Se realizó una revisión de la bibliografía publicada hasta la fecha sobre su manejo, hallándose, que, el metilfenidato es un fármaco seguro que, globalmente, puede reducir la fatiga en el paciente paliativo, con un perfil de efectos secundarios tolerable.Descargas
Citas
1. RADBRUCH L, STRASSER F, ELSNER F, GONÇALVES JF, LØGE J, KAASA S, NAUCK F, STONE P. Research steering committee of the European Association for Palliative Care (EAPC). Fatigue in palliative care patients -- an EAPC approach. Palliat Med 2008; 22: 13-32.
https://doi.org/10.1177/0269216307085183
2. MINTON O, RICHARDSON A, SHARPE M, HOTOPF M, STONE P.A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue. J Natl Cancer Inst 2008 20; 100: 1155-1166.
https://doi.org/10.1093/jnci/djn250
3. PEUCKMANN V, ELSNER F, KRUMM N, TROTTENBERG P, RADBRUCH L. Pharmacological treatments for fatigue associated with palliative care. Cochrane Database Syst Rev 2010; (11): CD006788.
4. PORTELA MA, RUBIALES AS, CENTENO C. The use of psychostimulants in cancer patients. Curr Opin Support Palliat Care 2011; 5: 164-168.
https://doi.org/10.1097/SPC.0b013e3283462ff3
5. SOOD A, BARTON DL, LOPRINZI CL. Use of methylphenidate in patients with cancer. Am J Hosp Palliat Care 2006; 23: 35-40.
https://doi.org/10.1177/104990910602300106
6. HARRIS JD. Fatigue in chronically ill patients. Curr Opin Support Palliat Care 2008; 2: 180-186.
https://doi.org/10.1097/SPC.0b013e32830baed0
7. BREITBART W, ALICI Y. Pharmacologic treatment options for cancer-related fatigue: current state of clinical research. Clin J Oncol Nurs 2008; 12 (5 Suppl): 27-36.
https://doi.org/10.1188/08.CJON.S2.27-36
8. HARDY SE. Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults. Am J Geriatr Pharmacother 2009; 7: 34-59.
https://doi.org/10.1016/j.amjopharm.2009.02.006
9. ROTH AJ, NELSON C, ROSENFELD B, SCHER H, SLOVIN S, MORRIS M et al. Methylphenidate for fatigue in ambulatory men with prostate cancer. Cancer 2010; 116: 5102-5110.
https://doi.org/10.1002/cncr.25424
10. WAGNER GJ, RABKIN JG, RABKIN R. Dextroamphetamine as a treatment for depression and low energy in AIDS patients: a pilot study. J Psychosom Res 1997; 42: 407-411.
https://doi.org/10.1016/S0022-3999(96)00366-2
11. BRUERA E, VALERO V, DRIVER L, SHEN L, WILLEY J, ZHANG T et al. Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol 2006; 24: 2073-2078.
https://doi.org/10.1200/JCO.2005.02.8506
12. BUTLER JM JR, CASE LD, ATKINS J, FRIZZELL B, SANDERS G, GRIFFIN P et al. A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy. Int J Radiat Oncol Biol Phys 2007; 69: 1496-1501.
https://doi.org/10.1016/j.ijrobp.2007.05.076
13. AURET KA, SCHUG SA, BREMNER AP, BULSARA M. A randomized, double-blind, placebo-controlled trial assessing the impact of dexamphetamine on fatigue in patients with advanced cancer. J Pain Symptom Manage 2009; 37: 613-621.
https://doi.org/10.1016/j.jpainsymman.2008.03.016
14. MINTON O, RICHARDSON A, SHARPE M, HOTOPF M, STONE PC. Psychostimulants for the management of cancer-related fatigue: a systematic review and meta-analysis. J Pain Symptom Manage 2011; 41: 761-767.
https://doi.org/10.1016/j.jpainsymman.2010.06.020
15. LOWER EE, FLEISHMAN S, COOPER A, ZELDIS J, FALECK H, YU Z et al. Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial. J Pain Symptom Manage. 2009; 38: 650-662.
https://doi.org/10.1016/j.jpainsymman.2009.03.011
16. MORASKA AR, SOOD A, DAKHIL SR, SLOAN JA, BARTON D, ATHERTON PJ et al. Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial. J Clin Oncol 2010; 28: 3673-3679.
https://doi.org/10.1200/JCO.2010.28.1444
17. LAVAL G, PARIS A. [Methylphenidate in palliative care in cancer patient: a double-blind randomised trial versus placebo]. Bull Cancer 2008; 95: 241-246.
18. LASHEEN W, WALSH D, MAHMOUD F, DAVIS MP, RIVERA N, KHOSHKNABI DS. Methylphenidate side effects in advanced cancer: a retrospective analysis. Am J Hosp Palliat Care 2010; 27: 16-23.
https://doi.org/10.1177/1049909109345145
19. CUEVA JF, CALVO M, ANIDO U, LEÓN L, GALLARDO E, ARESES C et al. Methylphenidate in the management of asthenia in breast cancer patients treated with docetaxel: results of a pilot study. Invest New Drugs 2012; 30: 688-694.
https://doi.org/10.1007/s10637-010-9539-7
20. YENNURAJALINGAM S, PALMER JL, CHACKO R, BRUERA E. Factors associated with response to methylphenidate in advanced cancer patients. Oncologist 2011; 16: 246-253.
https://doi.org/10.1634/theoncologist.2010-0214
21. JOHNSON RL, BLOCK I, GOLD MA, MARKWELL S, ZUPANCIC M. Effect of methylphenidate on fatigue in women with recurrent gynecologic cancer. Psychooncology 2010; 19: 955-958.
https://doi.org/10.1002/pon.1646
22. KERR CW, DRAKE J, MILCH RA, BRAZEAU DA, SKRETNY JA, BRAZEAU GA et al. Effects of methylphenidate on fatigue and depression: a randomized, double-blind, placebo-controlled trial. J Pain Symptom Manage 2012; 43: 68-77.
https://doi.org/10.1016/j.jpainsymman.2011.03.026
23. PORTELA MA, SANZ A, MARTÍNEZ M, CENTENO C. Astenia en cáncer avanzado y uso de psicoestimulantes. An Sist Sanit Navar 2011; 34: 471-479.
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2013 Anales del Sistema Sanitario de Navarra
Esta obra está bajo una licencia internacional Creative Commons Atribución-CompartirIgual 4.0.
La revista Anales del Sistema Sanitario de Navarra es publicada por el Departamento de Salud del Gobierno de Navarra (España), quien conserva los derechos patrimoniales (copyright ) sobre el artículo publicado y favorece y permite la difusión del mismo bajo licencia Creative Commons Reconocimiento-CompartirIgual 4.0 Internacional (CC BY-SA 4.0). Esta licencia permite copiar, usar, difundir, transmitir y exponer públicamente el artículo, siempre que siempre que se cite la autoría y la publicación inicial en Anales del Sistema Sanitario de Navarra, y se distinga la existencia de esta licencia de uso.
